06:05 EDT Kairos Pharma (KAPA) files to sell 16.29M shares of common stock for holders
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KAPA:
- Kairos Pharma: Promising Oncology Pipeline and Strategic Advancements Drive Buy Rating
- Kairos Pharma: Promising Innovations in Cancer Drug Resistance and Immune Enhancement
- Block upgraded, Nvidia downgraded: Wall Street’s top analyst calls
- Kairos Pharma initiated with a Buy at H.C. Wainwright
- Promising Developments and Strategic Trials Propel Kairos Pharma’s Buy Rating